Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Accounts Payables: 2023-2024

Historic Accounts Payables for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $5.6 million.

  • BioLineRx's Accounts Payables fell 44.70% to $3.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.5 million, marking a year-over-year decrease of 44.70%. This contributed to the annual value of $5.6 million for FY2024, which is 48.63% down from last year.
  • As of FY2024, BioLineRx's Accounts Payables stood at $5.6 million, which was down 48.63% from $10.9 million recorded in FY2023.
  • In the past 5 years, BioLineRx's Accounts Payables registered a high of $10.9 million during FY2023, and its lowest value of $5.6 million during FY2024.
  • Moreover, its 2-year median value for Accounts Payables was $8.2 million (2023), whereas its average is $8.2 million.
  • Data for BioLineRx's Accounts Payables shows a maximum YoY slumped of 48.63% (in 2024) over the last 5 years.
  • Over the past 2 years, BioLineRx's Accounts Payables (Yearly) stood at $10.9 million in 2023, then crashed by 48.63% to $5.6 million in 2024.